{"id":"https://openalex.org/W2557734048","doi":"https://doi.org/10.1182/blood.v108.11.2466.2466","title":"Cutaneous T Cell Lymphoma: Responses in Phase 1 Trial of Combination Therapy with Liposomal Doxorubicin, Bortezomib, and Gemcitabine.","display_name":"Cutaneous T Cell Lymphoma: Responses in Phase 1 Trial of Combination Therapy with Liposomal Doxorubicin, Bortezomib, and Gemcitabine.","publication_year":2006,"publication_date":"2006-11-01","ids":{"openalex":"https://openalex.org/W2557734048","doi":"https://doi.org/10.1182/blood.v108.11.2466.2466","mag":"2557734048"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v108.11.2466.2466","doi":"https://doi.org/10.1182/blood.v108.11.2466.2466","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.2466.2466","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Navneet Dhillon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Navneet Dhillon","raw_affiliation_strings":["Phase 1, M.D Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Phase 1, M.D Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077381959","display_name":"Srinivasa Bakkannagari","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Srinivasa Bakkannagari","raw_affiliation_strings":["Phase 1, M.D Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Phase 1, M.D Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053460346","display_name":"Chaan S. Ng","orcid":"https://orcid.org/0000-0001-9261-7021","observed_orcids":["https://orcid.org/0000-0001-9261-7021"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Chaan Ng","raw_affiliation_strings":["Radiology, M.D Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Radiology, M.D Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109214096","display_name":"Joann T. Lim","orcid":"https://orcid.org/0000-0001-7983-3264","observed_orcids":["https://orcid.org/0000-0001-7983-3264"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Joann Lim","raw_affiliation_strings":["Pharmacy, M.D. Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacy, M.D. Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030460763","display_name":"Madeleine A. Duvic","orcid":"https://orcid.org/0000-0002-8971-4565","observed_orcids":["https://orcid.org/0000-0002-8971-4565"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Madeline Duvic","raw_affiliation_strings":["Dermatology, M.D. Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology, M.D. Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["Phase 1, M.D Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Phase 1, M.D Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5030460763","https://openalex.org/A5053460346","https://openalex.org/A5077381959","https://openalex.org/A5109214096"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.7061,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.75645161,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"108","issue":"11","first_page":"2466","last_page":"2466"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cutaneous-t-cell-lymphoma","display_name":"cutaneous T-cell lymphoma","score":0.9539999961853027},{"id":"https://openalex.org/keywords/liposomal-doxorubicin","display_name":"liposomal doxorubicin","score":0.9890000224113464},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9589999914169312},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":1.0},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7820000052452087},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.8309999704360962},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6600000262260437},{"id":"https://openalex.org/keywords/partial-remission","display_name":"partial remission","score":0.7059999704360962},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.7480000257492065},{"id":"https://openalex.org/keywords/sepsis","display_name":"sepsis","score":0.7850000262260437},{"id":"https://openalex.org/keywords/heavily-pretreated-patients","display_name":"heavily pretreated patients","score":0.6510000228881836},{"id":"https://openalex.org/keywords/advanced-disease","display_name":"advanced disease","score":0.5529999732971191},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.47999998927116394},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.3499999940395355}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9065505266189575},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.7810272574424744},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7596073150634766},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.7275661826133728},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6344552636146545},{"id":"https://openalex.org/C2776780870","wikidata":"https://www.wikidata.org/wiki/Q5196687","display_name":"Cutaneous T-cell lymphoma","level":4,"score":0.46150970458984375},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44549113512039185},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4400619864463806},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.43976473808288574},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.37940892577171326},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3673458695411682},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3483361601829529},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.31248003244400024},{"id":"https://openalex.org/C2777756187","wikidata":"https://www.wikidata.org/wiki/Q1891209","display_name":"Mycosis fungoides","level":3,"score":0.20888012647628784}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v108.11.2466.2466","doi":"https://doi.org/10.1182/blood.v108.11.2466.2466","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.2466.2466","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2057290270","https://openalex.org/W1988421014","https://openalex.org/W1749229087","https://openalex.org/W1979501547","https://openalex.org/W2424848057","https://openalex.org/W4400694646","https://openalex.org/W1986043360","https://openalex.org/W2040390735","https://openalex.org/W4223631976","https://openalex.org/W4310103738"],"abstract_inverted_index":{"Abstract":[0],"BACKGROUND:":[1],"There":[2,62,107],"is":[3,227],"preclinical":[4],"data":[5],"suggesting":[6],"pro-apoptotic":[7],"synergy":[8],"between":[9],"the":[10,82,122,166,201,231],"proteosome":[11],"inhibitor":[12],"bortezomib,":[13],"doxorubucin":[14],"and":[15,51,70,101,165,191,250,252,259],"gemcitabine.":[16],"Therefore,":[17],"we":[18],"are":[19,52,120,163,168],"currently":[20],"conducting":[21],"a":[22,32,88,139,155],"Phase":[23],"I":[24],"dose":[25,79,89,92],"finding":[26],"trial":[27,116],"of":[28,34,66,73,124,141,149,160,180,206,279,286],"this":[29,35,115],"combination.":[30],"As":[31],"part":[33],"trial,":[36],"high":[37],"response":[38],"rates":[39],"with":[40,127,138,212],"excellent":[41],"tolerance":[42],"were":[43,63,94,108,112,175],"noted":[44],"in":[45,95,200,262,270,288],"advanced":[46,210,265],"cutaneous":[47,128,266],"T-":[48],"cell":[49,130],"lymphoma,":[50],"presented":[53],"here.":[54],"METHODS:":[55],"A":[56],"3+":[57],"3":[58,303],"design":[59],"was":[60,78],"used.":[61],"two":[64],"cohorts":[65],"patients:":[67],"<":[68],"65":[69],"\u226565":[71],"years":[72],"age.":[74],"The":[75,171,224],"older":[76],"cohort":[77,84],"escalated":[80],"after":[81,316],"younger":[83],"demonstrated":[85],"safety":[86],"at":[87],"level.":[90],"Initial":[91],"escalations":[93],"bortezomib":[96,253],"alone,":[97],"followed":[98],"by":[99,103],"gemcitabine,":[100],"then":[102],"liposomal":[104],"doxorubicin.":[105],"RESULTS:":[106],"33":[109],"patients":[110,126,133,152,167,196,208],"who":[111],"treated":[113],"on":[114,242,247,256],"to":[117,230,305,313],"date.":[118],"We":[119],"reporting":[121],"results":[123],"7":[125],"T":[129,272],"lymphoma.":[131,268],"These":[132],"had":[134,209],"been":[135,221],"heavily":[136,263],"pretreated":[137],"median":[140],"6":[142,300,330],"prior":[143,280],"therapies":[144,281],"(range":[145],"1\u201312).":[146],"All":[147,205],"six":[148,150],"evaluable":[151],"(100%)":[153],"achieved":[154],"partial":[156],"remission":[157],"(PR).":[158],"Some":[159],"these":[161,207],"responses":[162],"ongoing":[164],"still":[169],"improving.":[170],"most":[172],"common":[173],"toxicities":[174],"grade":[176,182],"2":[177,311,317,322,323,331],"thrombocytopenia":[178],"(50%":[179],"patients),":[181,186,190],"1\u20132":[183],"fatigue":[184],"(44%":[185],"grade1\u20132":[187],"mucositis":[188],"(14%":[189],"myelosuppression":[192],"(12%":[193],"patients).":[194],"Four":[195],"needed":[197],"hospitalization":[198],"early":[199],"course":[202],"for":[203],"sepsis.":[204],"disease":[211],"ulcerating":[213],"skin":[214],"lesions.":[215],"Dose":[216,282],"limiting":[217],"toxicity":[218],"has":[219,260],"not":[220],"seen.":[222],"CONCLUSIONS:":[223],"above":[225],"combination":[226],"safe":[228],"up":[229,315],"doses":[232,318],"tested":[233],"so":[234],"far-":[235],"(dose":[236],"level":[237],"5":[238,339,345,346],"=":[239],"doxil":[240],"24mg/m2":[241],"day1,":[243],"gemcitabine":[244],"800":[245],"mg/m2":[246,255],"days":[248,257],"1":[249,294,301,338],"8":[251,310],"1.0":[254],"1,4,8,11)":[258],"activity":[261],"pretreated,":[264],"T-Cell":[267],"Responses":[269],"Cutaneous":[271],"Cell":[273],"Lymphoma":[274],"Age":[275],"Sex":[276],"Stage":[277],"Number":[278],"Level":[283],"Response":[284],"Duration":[285],"therapy":[287],"months":[289],"71":[290],"F":[291,298,308,343],"IV":[292,299,309,321,328,344],"12":[293],"PR":[295,302,324,332,340,347],"4":[296],"32":[297],"(sent":[304],"BMT)":[306],"61":[307],"Lost":[312],"follow":[314],"72":[319],"M":[320,327,335],"7+":[325,341],"73":[326],"B":[329,337],"4+":[333],"53":[334],"II":[336],"60":[342],"8+":[348]},"counts_by_year":[{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2016-12-08T00:00:00"}